Amicus Therapeutics (NASDAQ:FOLD) had its price objective hoisted by HC Wainwright from $18.00 to $20.00 in a report released on Tuesday, Briefing.com Automated Import reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other research analysts have also recently issued reports on FOLD. Cantor Fitzgerald reissued an overweight rating on shares of Amicus Therapeutics in a research report on Thursday, October 17th. Zacks Investment Research raised Amicus Therapeutics from a hold rating to a buy rating and set a $9.25 target price on the stock in a research report on Monday, November 4th. Cowen set a $31.00 target price on Amicus Therapeutics and gave the stock a buy rating in a research report on Thursday, October 10th. ValuEngine cut Amicus Therapeutics from a buy rating to a hold rating in a research report on Friday, November 8th. Finally, BidaskClub raised Amicus Therapeutics from a sell rating to a hold rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $17.97.
FOLD traded up $0.22 during trading on Tuesday, reaching $9.57. The stock had a trading volume of 3,073,900 shares, compared to its average volume of 2,514,296. The company has a market capitalization of $2.43 billion, a price-to-earnings ratio of -7.20 and a beta of 1.58. The company has a current ratio of 6.20, a quick ratio of 6.97 and a debt-to-equity ratio of 0.36. The stock’s 50 day moving average is $8.40 and its two-hundred day moving average is $10.76. Amicus Therapeutics has a one year low of $7.11 and a one year high of $14.61.
In other news, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $10.05, for a total value of $201,000.00. Following the transaction, the chief executive officer now owns 770,194 shares of the company’s stock, valued at $7,740,449.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Burke W. Whitman acquired 4,945 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was bought at an average cost of $10.07 per share, for a total transaction of $49,796.15. Following the purchase, the director now directly owns 21,612 shares of the company’s stock, valued at $217,632.84. The disclosure for this purchase can be found here. Insiders sold 54,500 shares of company stock worth $497,545 in the last ninety days. Corporate insiders own 2.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Point72 Hong Kong Ltd bought a new position in shares of Amicus Therapeutics in the second quarter worth about $49,000. US Bancorp DE raised its stake in shares of Amicus Therapeutics by 50.9% in the second quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,651 shares during the period. Meeder Asset Management Inc. bought a new position in shares of Amicus Therapeutics in the second quarter worth about $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new position in shares of Amicus Therapeutics in the second quarter worth about $122,000. Finally, Weil Company Inc. bought a new position in shares of Amicus Therapeutics in the second quarter worth about $125,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Article: What is a dividend reinvestment plan?
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.